Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery

por Turpie, Alexander GG, Schmidt, André C, Kreutz, Reinhold, Lassen, Michael R, Jamal, Waheed, Mantovani, Lorenzo, Haas, Sylvia
Publicado 2012

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

por Packer, Milton, Butler, Javed, Filippatos, Gerasimos, Zannad, Faiez, Ferreira, Joao Pedro, Zeller, Cordula, Brueckmann, Martina, Jamal, Waheed, Pocock, Stuart J., Anker, Stefan D.
Publicado 2020

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

por Abraham, William T., Ponikowski, Piotr, Brueckmann, Martina, Zeller, Cordula, Macesic, Hemani, Peil, Barbara, Brun, Michèle, Ustyugova, Anastasia, Jamal, Waheed, Salsali, Afshin, Lindenfeld, JoAnn, Anker, Stefan D.
Publicado 2019

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozi...

por Packer, Milton, Januzzi, James L., Ferreira, Joao Pedro, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J., Brueckmann, Martina, Jamal, Waheed, Cotton, Daniel, Iwata, Tomoko, Zannad, Faiez
Publicado 2021

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

por Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J, Rocca, Hans-Peter Brunner-La, Janssens, Stefan, Tsutsui, Hiroyuki, Zhang, Jian, Brueckmann, Martina, Jamal, Waheed, Cotton, Daniel, Iwata, Tomoko, Schnee, Janet, Zannad, Faiez
Publicado 2021

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

por Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, Zannad, Faiez
Publicado 2020

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

por Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Ferreira, João Pedro, Pocock, Stuart J, Giannetti, Nadia, Januzzi, James L, Piña, Ileana L, Lam, Carolyn S P, Ponikowski, Piotr, Sattar, Naveed, Verma, Subodh, Brueckmann, Martina, Jamal, Waheed, Vedin, Ola, Peil, Barbara, Zeller, Cordula, Zannad, Faiez, Packer, Milton
Publicado 2021

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial

por Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Marx, Nikolaus, Lam, Carolyn S.P., Schnaidt, Sven, Ofstad, Anne Pernille, Brueckmann, Martina, Jamal, Waheed, Bocchi, Edimar A., Ponikowski, Piotr, Perrone, Sergio V., Januzzi, James L., Verma, Subodh, Böhm, Michael, Ferreira, João Pedro, Pocock, Stuart J., Zannad, Faiez, Packer, Milton
Publicado 2020